Cardioprotection: Bariatric Surgery Wins the Long Game

GLP-1 Medications took the weight loss community by storm, and they offer tremendous benefits for the right candidates. However, for those with severe obesity and obesity-related health conditions, bariatric surgery offers the most hope – not just for diabetes remission or lowering cholesterol, but also for protecting heart health and lowering the risk of future cardiovascular events.

As bariatric surgeons, we know the benefits of weight loss surgery. Even though it’s in the name, we know that it’s more than just weight loss. It’s a new lease on life and a chance to gain back your health.

Weight loss is front and center in the context of bariatric surgery, the lifestyle modifications, the diets, and even GLP-1 medications, but these tools and the effort you put into them also offer incredible health improvements. One of those is long-lasting cardiovascular effects.

A Heavy Heart

Obesity puts additional strain on the body, and that includes the cardiovascular system. The heart already works relentlessly, day in and day out, but severe excess body weight increases the demands placed on every part of that system.

Along with an increase in body mass, blood volume rises, vascular resistance increases, and chronic inflammation disrupts normal cardiovascular function. Hormonal pathways become overactivated, blood vessels lose their ability to dilate properly, and the heart has to pump harder. The longer this goes on, the more you increase your chances for hypertension, arterial damage, and structural remodeling of the heart itself. A cascade of disruption ensues.

Elevated blood pressure and chronic inflammation accelerate atherosclerosis. This is when cholesterol plaques form within arterial walls, narrowing blood flow and stiffening vessels. If coronary artery disease develops, oxygen to the heart muscle becomes limited, increasing the risk of angina, arrhythmias, heart attack, and heart failure.

Obesity also creates a prothrombotic state where the aforementioned plaque ruptures. Dangerous clot formation is more likely and increases the chance of having a stroke. The potential structural changes within the heart can disrupt electrical signaling and contribute to arrhythmias like atrial fibrillation. These conditions develop gradually, so most people are unaware that it’s happening before it presents as a major cardiovascular event.

There is a silver lining of sorts — obesity-related cardiovascular disease is not entirely irreversible. Even modest weight loss can improve blood pressure, lipid levels, insulin sensitivity, inflammation, and overall cardiac workload. The cardiovascular system is remarkably adaptive, and reducing excess weight significantly lowers the burden while decreasing the risk of future disease.

The Long Game

GLP-1 therapy and bariatric surgery are both effective treatments for obesity that can improve heart health by promoting weight loss, correcting blood sugar, lowering blood pressure, and improving cholesterol levels. While both methods improve cardiovascular risk factors, recent research shows that bariatric surgery tends to offer longer-lasting heart protection, mainly because it leads to greater and more lasting weight loss.^1-2

They’ve been on the market for several years now, and most people are well-versed in what GLP-1 RAs do – reduce appetite, improve insulin sensitivity, and support weight loss. However, the weight loss from GLP-1 therapy is usually less than what is seen with bariatric surgery, and the benefits often depend on staying on the medication. Recent studies show that stopping GLP-1 drugs can lead to rapid weight regain and quickly take away some of their heart benefits. Researchers have also noted that the risks may go up after stopping the medication, and not just because of the rebounding weight gain.³

Meanwhile, bariatric surgery has a long track record of greater consistency in treating both obesity and cardiovascular disease risk. In a study evaluating 812 adults with obesity, those who had bariatric surgery lost almost 28% of their body weight, while those on GLP-1 medications lost about 11%. Even more interesting, the lifetime risk of heart disease dropped by 8.6% after surgery, compared to a 1.7% drop with GLP-1 therapy. And it doesn’t stop there. The study also found that greater weight loss is associated with even greater reductions in heart disease risk, especially among people who lost more than 20% of their body weight.⁴ The same study confirmed that bariatric surgery led to greater reductions in lifetime risk of atherosclerotic heart disease, even after accounting for starting BMI and other risk factors. Surgery also improved cholesterol and overall metabolic health more than medication.⁵

In addition to remission rates of obesity-related conditions such as type 2 diabetes, hypertension, and hyperlipidemia following surgery, multiple studies and meta-analyses also show reductions in myocardial infarction (heart attack), stroke, and even mortality rates by 40%, including a 56% reduction in coronary artery disease-related death.⁶

GLP-1 medications are a highly effective treatment option for the appropriate candidates; there’s no doubt about that. However, for individuals with severe obesity requiring substantial and durable weight reduction to reduce obesity-related health conditions and alter cardiovascular risk trajectories, current evidence suggests that bariatric surgery is the gold standard for offering the strongest long-term cardioprotective effects.

GLP-1 receptor agonists (GLP-1 RAs) and bariatric surgery are incredibly beneficial for appropriate patients, but it also takes long-term lifestyle changes and medical guidance. If you’re ready to take control of your health and explore medically guided weight loss options, the team at Strive Surgery can help you build a strategy designed for long-term success.

Las Vegas-based Shawn Tsuda, MD, MBA, FACS is a board-certified general surgeon who specializes in minimally invasive and robotic procedures for weight loss, reflux disease, and hernia repair. He performs advanced bariatric surgeries such as sleeve gastrectomy and gastric bypass, along with anti-reflux procedures like LINX. He is also actively involved in surgical education, training other surgeons, and contributing to national organizations in gastrointestinal and endoscopic surgery.

1. Raza, F. A., Altaf, R., Bashir, T., Asghar, F., Altaf, R., Tousif, S., Goyal, A., Mohammed, A., Mohammad, M. F., Anan, M., & Ali, S. (2024). Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review. Medicine, 103(44), e40364. https://doi.org/10.1097/MD.0000000000040364.
2. Kuno, T., Tanimoto, E., Morita, S., & Shimada, Y. J. (2019). Effects of Bariatric Surgery on Cardiovascular Disease: A Concise Update of Recent Advances. Frontiers in cardiovascular medicine, 6, 94. https://doi.org/10.3389/fcvm.2019.00094.
3. Ballard, S. (2026, March 18). Stopping GLP-1 drugs can quickly erase cardiovascular benefits. WashU Medicine. https://medicine.washu.edu/news/stopping-glp-1-drugs-can-quickly-erase-cardiovascular-benefits/.
4. Corey, C. (2026, April 28). Mayo Clinic study finds bariatric surgery associated with greater long-term heart risk reduction than weight-loss medications. Mayo Clinic News Network. https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-study-finds-bariatric-surgery-associated-with-greater-long-term-heart-risk-reduction-than-weight-loss-medications/.
5. Ghusn, W., Vierkant, R. A., Jawhar, N., Abedalqader, T., El Ghazal, N., Espinosa, M. A., Villamarin, J., Gutierrez, R. R., Castaneda, R., Bechenati, D., Fansa, S., Hurtado, M. D., Acosta, A., & Ghanem, O. M. (2026). Metabolic and Bariatric Surgery vs Glucagon-like peptide-1 Receptor Agonist Therapy. Annals of Surgery. https://doi.org/10.1097/sla.0000000000007064.
6. Kuno, T., Tanimoto, E., Morita, S., & Shimada, Y. J. (2019). Effects of Bariatric Surgery on Cardiovascular Disease: A Concise Update of Recent Advances. Frontiers in cardiovascular medicine, 6, 94. https://doi.org/10.3389/fcvm.2019.00094.